AbbVie, Inc. Hits New 52-Week High at $255.99, Up 49.19%

AbbVie, Inc., a prominent player in the Pharmaceuticals & Biotechnology sector, has reached a significant milestone by hitting a new 52-week high of USD 255.99 on June 29, 2026. This achievement underscores the company's robust performance over the past year, with a remarkable increase of 49.19%, significantly outpacing the S&P 500's growth of 20.53% during the same period. With a market capitalization of USD 377,369 million, AbbVie stands as a large-cap entity in its industry. The company's price-to-earnings (P/E) ratio is currently at 35.00, reflecting its valuation in the market. Additionally, AbbVie offers a dividend yield of 3.11%, which may appeal to income-focused investors. Despite the impressive stock performance, AbbVie has reported a negative return on equity of -326.10% and a debt-to-equity ratio of -19.03, indicating a complex financial landscape. The stock's 52-week low was recorded at USD 181.75, highlighting the significant upward movement in its price. Overall, AbbVie’s recent performance marks a notable chapter in its financial journey.